Alluvi, previously BI 4744, offers a notable advance in obesity therapy. This dual stimulator targeting both glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptors demonstrates compelling https://alluvi-research.co.uk/product/alluvi-retatrutide-40mg-rd-only/